Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial (EAGLE Pilot)
|ClinicalTrials.gov Identifier: NCT01183637|
Recruitment Status : Terminated (Study enrollment rate was far slower than anticipated. Study was stopped for business purposes.)
First Posted : August 17, 2010
Last Update Posted : May 25, 2015
|Condition or disease||Intervention/treatment||Phase|
|Articular Cartilage Injury||Device: Kensey Nash Corp. Cartilage Repair Device Procedure: Microfracture||Phase 2|
Damage to articular cartilage in the knee by acute or chronic injury causes pain and limits knee function. If left untreated, damage to the articular cartilage can lead to painful osteoarthritis. The human body has a limited ability to regenerate or adequately repair damage to articular cartilage. There are several surgical techniques available to assist the repair of articular cartilage and improve pain and function. Microfracture is the most commonly used technique for cartilage repair. Microfracture involves the creation of numerous small fractures in the bone with a pick. These small fractures cause the release of multipotential stem cells from the bone marrow creating a clot on the surface. Over time, this clot causes reparative fibrocartilage to form. However, fibrocartilage is less durable and lacks the mechanical properties of normal articular cartilage. The majority of patients treated with microfracture has good results within the first 2 years after microfracture. However, beyond 2 years, functional deterioration is seen in over 50% of patients. Therefore, there is a clinical need for a product that improves surgical outcomes in patients with cartilage damage.
The Kensey Nash Corp. Cartilage Repair Device is a two layer, bioresorbable implant. The top layer consists of collagen fibers like those found in normal cartilage. The collagen layer is about as thick as the cartilage in human knees. The bottom layer of the Cartilage Repair Device mainly consists of a calcium mineral naturally found in human bones. The mineral is held within a biodegradable polymer material. The device has a highly porous structure that allows the blood, stem cells and joint fluid to infiltrate the device during the healing process. Over time, the top layer is designed to be replaced by cartilage and the bottom layer is designed to be replaced by bone.
Both microfracture and the Cartilage Repair Device are expected to reduce knee pain and increase knee function in a majority of patients during the first 2 years post-operative. However, if the Cartilage Repair Device produces better and more durable cartilage than the microfracture technique, those patients treated with the Cartilage Repair Device may have a better long term outcome.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Initial Safety and Effectiveness Study of the Kensey Nash Corp. Cartilage Repair Device for Knee Cartilage Lesion Repair|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||May 2014|
Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
Device: Kensey Nash Corp. Cartilage Repair Device
To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
Active Comparator: Control
Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
- Patient Success [ Time Frame: 24 months ]Improvement in pain, function, and cartilage defect appearance without any treatment related serious adverse events.
- Knee Injury and Osteoarthritic Outcome Score ("KOOS") [ Time Frame: 24 months ]Clinically significant improvement in the KOOS Pain, Activities of Daily Living, Symptoms, Sports & Recreation and Quality of Life subscale scores
- Cartilage defect appearance on MRI [ Time Frame: 24 months ]Cartilage defect filling, repair cartilage integration with surrounding native cartilage and presence of bony overgrowth will be assessed.
- Lyshom Score [ Time Frame: 24 months ]Clinical significant improvement in the Lysolm Knee Scale score
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01183637
|United States, Maryland|
|Peninsula Orthopedic Associates|
|Salisbury, Maryland, United States, 21804|
|United States, Missouri|
|U.S. Center for Sports Medicine|
|Kirkwood, Missouri, United States, 63122|
|Principal Investigator:||Richard C Lehman, M.D.||U.S. Center for Sports Medicine, Kirkwood, MO|
|Principal Investigator:||Phillip A Davidson, M.D.||Heiden - Davidson Orthopedics, Park City, UT|